Live Breaking News & Updates on Principal At Novo Holdings

Stay updated with breaking news from Principal at novo holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

SCHLIEREN, Switzerland, October 09, 2023 LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against increasingly dangerous bacterial infections, including programs addressing shigellosis and gonorr ....

United States , New York , City Of , United Kingdom , Alexander Siebert , Kabeer Aziz , Zina Affas Besse , Limmatech Biologics , Franz Werner Haas , Camilla Petrycer Hansen , Hooft Van Huijsduijnen , Limmatech Bio , Novo Holding , Principal At Novo Holdings , Impact Fund , National Overview , Infective Resistance Impact Fund , Novo Holdings , Novo Nordisk Foundation , World Health Organization , Trophic Communications , United States Centers For Disease , Adjuvant Capital , Affas Besse , Deputy Head , Private Equity ,

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidru

SCHLIEREN, Switzerland (BUSINESS WIRE) LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platfor. ....

United States , New York , City Of , United Kingdom , Zina Affas Besse , Camilla Petrycer Hansen , Kabeer Aziz , Limmatech Bio , Alexander Siebert , Hooft Van Huijsduijnen , Franz Werner Haas , Limmatech Biologics , Trophic Communications , Novo Holdings , Novo Holding , National Overview , United States Centers For Disease , World Health Organization , Impact Fund , Principal At Novo Holdings , Novo Nordisk Foundation , Infective Resistance Impact Fund , Adjuvant Capital , Affas Besse , Deputy Head , Private Equity ,

LimmaTech Biologics AG: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

LimmaTech Biologics AG: LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , New York , City Of , United Kingdom , Zina Affas Besse , Hooft Van Huijsduijnen , Camilla Petrycer Hansen , Alexander Siebert , Franz Werner Haas , Limmatech Bio , Limmatech Biologics , Kabeer Aziz , Novo Holdings , Trophic Communications , Novo Nordisk Foundation , United States Centers For Disease , World Health Organization , Impact Fund Home , Novo Holding , National Overview , Infective Resistance Impact Fund , Impact Fund , Principal At Novo Holdings , Adjuvant Capital , Affas Besse , Deputy Head ,

Evosep receives strategic investment from Novo Holding A/S to accelerate its effort on clinical proteomics

Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics. ....

Stephen Van Helden , Christian Ravnsborg , Danielle Ellis , Health Tech , Principal At Novo Holdings , Novo Holding , Investment Fund , Novo Holdings , From Evosepjan , Evosep Aps , Van Helden , Ole Vorm , Evosep One , Clinical Diagnostics , High Throughput ,